TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30872130
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of FR+-CTC count and maximum tumour diameter (MTD)
Study: 27227460
Drug: Electroacupuncture (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (EA) treatment, 3 weekly sessions
Study: 22126102
Drug: Brief Intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief Intervention (BI) for illicit drugs (cannabis, cocaine, amphetamine-type stimulants, opioids)
Study: 22126102
Drug: Brief Intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief Intervention (BI) for stimulants
Study: 18397695
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (133.3 mg lopinavir/33.3 mg ritonavir)
Study: 18397695
Drug: Reference product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference product (Kaletra 133.3 mg lopinavir/33.3 mg ritonavir)
Study: 15647968
Drug: Higher molecular
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher molecular weight viscosupplement (hylan G‐F 20, Synvisc)
Study: 9174876
Drug: Aerosolized heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized heparin inhalation (1,000 U/kg)
Study: 2677269
Drug: Empiric care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empiric care (high-dose antacid therapy: 15-30 ml of high-potency antacid one and three hours after meals and at bedtime)
Study: 30657120
Drug: 1 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml/kg of 0.25% caudal bupivacaine mixed with 2 μg/kg neostigmine (group BN)
Study: 30657120
Drug: 1 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml/kg of 0.25% caudal bupivacaine mixed with 50 mcg/kg midazolam (group BM)
Study: 30657120
Drug: 1 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml/kg of 0.25% caudal bupivacaine mixed with 0.5 mg/kg ketamine (group BK)
Study: 30657120
Drug: 1 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml/kg of 0.25% caudal bupivacaine (group B)
Study: 29911776
Drug: Multi-concentration level
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-concentration level patch test guided DPCP treatment
Study: 29911776
Drug: Conventional DPCP
Normalized name: DPCPX
DrugBank: DPCPX (DB12946)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional DPCP treatment
Study: 26123919
Drug: Single-dose study
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose study in men
Study: 23473374
Drug: 0.5 mg/ml
Normalized name: urea 0.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/ml mitomycin C (MMC) applied at the site of discectomy for 5 minutes
Study: 19594864
Drug: Probiotic group
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic group (L. gasseri CECT5714 and L. coryniformis CECT5711)
Study: 2801589
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate supplement (1500 mg Ca/d)
Study: 28376732
Drug: Daily consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily consumption of vegetables with dinner
Study: 23647285
Drug: Antidepressant Medications
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant Medications (ADMs)
Study: 23350342
Drug: Parathyroid hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Parathyroid hormone (PTH) 1-84
Study: 19482956
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral care with 0.12% chlorhexidine digluconate
Study: 19482956
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral care plus electric toothbrushing
Study: 12441260
Drug: VAC (vincristine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAC (vincristine, doxorubicin, cyclophosphamide) and VIAc (vincristine, ifosfamide, actinomycin) chemotherapy regimen
Study: 12441260
Drug: Surgery, surgery+radiotherapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery, surgery+radiotherapy, or radiotherapy only as local treatment
Study: 12441260
Drug: Previous studies
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Previous studies with three-drug VAC regimen (REA-1) and four-drug VACAc regimen (REA-2 and REN-1)
Study: 12441260
Drug: Previous study
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Previous study (REN-2) with a six-drug regimen
Study: 10515844
Drug: GM‐CSF plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM‐CSF plus sodium stibogluconate (20 mg/kg‐1/day‐1 for 20 days)
Study: 10515844
Drug: Placebo (saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline) plus sodium stibogluconate (20 mg/kg‐1/day‐1 for 20 days)
Study: 7722140
Drug: NG-mononmethyl-L-arginine (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: NG-mononmethyl-L-arginine (16 mumol/min) in untreated patients
Study: 7722140
Drug: NG-mononmethyl-L-arginine (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: NG-mononmethyl-L-arginine (16 mumol/min) in control subjects
Study: 7722140
Drug: NG-mononmethyl-L-arginine (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: NG-mononmethyl-L-arginine (16 mumol/min) in treated patients
Study: 1723464
Drug: Nitrendipine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (2 x 10 mg daily)
Study: 7347558
Drug: Amantadine 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine 300 mg/day
Study: 7347558
Drug: Rimantadine 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimantadine 300 mg/day
Study: 6746357
Drug: Radiotherapy (first
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy (first 10 Gy in five consecutive daily fractions)
Study: 24584549
Drug: Sitagliptin (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin (single oral dose)
Study: 21770837
Drug: Minimal stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal stimulation protocol (5 days CC 100 mg/day then 150 IU uFSH on cycle day 9)
Study: 21970545
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) only
Study: 19952860
Drug: Hib-MenC-TT vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hib-MenC-TT vaccine coadministered with MMR vaccine
Study: 17224218
Drug: MMR vaccine
Normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMR vaccine alone
Study: 15763054
Drug: Somatostatin administered
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin administered intravenously at a dosage of 250 mug/h for consecutive 72 hours
Study: 15763054
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group treated with non-surgical integrated traditional Chinese and Western medicine
Study: 12428174
Drug: Pyridoxine supplementation
Normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pyridoxine supplementation (25 mg/day) for 45 days
Study: 7781401
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy with etoposide/cisplatin
Study: 7781401
Drug: Chemotherapy/chest irradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy/chest irradiation
Study: 7781401
Drug: Surgery as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery as sole treatment
Study: 2340741
Drug: 1.0 U
Normalized name: Nutren 1.0 Ultrapak
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 U heparin/mL
Study: 2340741
Drug: 0.25 U
Normalized name: collagenase 0.25 UNT/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 U heparin/mL
Study: 30843921
Drug: MMR-Bio vaccine
Normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMR-Bio vaccine
Study: 24437236
Drug: Cefixime (suprax
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime (suprax solutab) 400 mg 1 time a day for 7 days
Study: 24437236
Drug: Amoxicillin/clavulanate (amoksiklav)
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate (amoksiklav) 625 mg 3 times a day for 7 days
Study: 17513537
Drug: Topical morphine
Normalized name: morphine Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical morphine sulphate
Study: 17513537
Drug: Intrasite gel
Normalized name: Intrasite Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrasite gel and water (placebo)
Study: 15309452
Drug: NUTRIOSE FB
Normalized name: FB-825
DrugBank: FB-825 (DB17598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NUTRIOSE FB (low-digestible carbohydrate) at a level of 100 g DM/d
Study: 12058086
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of W-P MCV and W-P SCV
Study: 10418043
Drug: Acyclovir (ACV)
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acyclovir (ACV) secondary prophylaxis, mean posology 2,400 mg (1,600‐4,000) per day, during mean 10 months (median 4 months)
Study: 7574048
Drug: PCHE equivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCHE equivalent to activity present in 2.5, 5, 7.5, 15, or 25 ml/kg of human plasma
Study: 7574048
Drug: PCHE equivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCHE equivalent to activity present in 25 ml/kg of human plasma
Study: 27779456
Drug: Lercanidipine 10
Normalized name: lercanidipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lercanidipine 10 mg/day
Study: 27779456
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (other antihypertensive treatments)
Study: 22251379
Drug: Inductive reasoning
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inductive reasoning training supplemented by weekly crossword and Sudoku puzzles
Study: 12856494
Drug: Sham treatment;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment; duration not specified.
Study: 10862808
Drug: Disulfiram (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disulfiram (250 mg q.d., n = 11)
Study: 10862808
Drug: Disulfiram (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disulfiram (250 mg q.d.)
Study: 9195495
Drug: RT plus
Normalized name: Recort Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT plus DBD (200 mg/m2 orally on Days 1-10 every five weeks)
Study: 9195495
Drug: RT plus
Normalized name: Recort Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT plus BCNU (200 mg/m2 intravenously every seven weeks)
Study: 26073422
Drug: Surgical periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical periodontal treatment
Study: 19422355
Drug: Ketamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.5 mg/kg i.v. bolus)
Study: 16399963
Drug: Adherent to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adherent to medication
Study: 16399963
Drug: Nonadherent to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonadherent to medication
Study: 10654983
Drug: Intranasal beclomethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal beclomethasone dipropionate (BDP) 168 microg twice daily (n = 51)
Study: 10654983
Drug: Intranasal beclomethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal beclomethasone dipropionate (BDP)
Study: 8342393
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment, 0.018 IU/kg/day for 1 month followed by 0.036 IU/kg/day for 1 month
Study: 2872717
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of synthetic somatostatin
Study: 2872717
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of secretin (280 pmol/kg‐h)
Study: 2872717
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of cholecystokinin (pharmacological dose)
Study: 2872717
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of gastric inhibitory polypeptide (GIP) (physiological range)
Study: 31197249
Drug: Antibiotic group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic group (omeprazole, amoxicillin, and clarithromycin; n=201)
Study: 30124726
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg Toreforant
Study: 30124726
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg Toreforant
Study: 26795846
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (placebo or medical treatment only)
Study: 16194413
Drug: Benazepril (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril (10-20 mg/d) in group A (Scr 133-265 micromol/L)
Study: 16194413
Drug: Benazepril (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril (10-20 mg/d) in group B1 (Scr 266-442 micromol/L)
Study: 16194413
Drug: Calcium-channel antagonist
Normalized name: Channel catfish
DrugBank: Channel catfish (DB15548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium-channel antagonist and/or beta-blocker and/or vasodilator in group B2 (control group)
Study: 12598257
Drug: Large-dose gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large-dose gentamicin (4 mg/kg)
Study: 12598257
Drug: Modest-dose gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modest-dose gentamicin (1.2 mg/kg)
Study: 8470311
Drug: Chloroquine and
Normalized name: chloroquine and proguanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine and Proguanil combination (CQ+PROG)
Study: 2983910
Drug: Etomidate (0.26
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate (0.26 mg/kg i.v.)
Study: 2983910
Drug: Thiopentone (5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopentone (5.0 mg/kg i.v.)
Study: 30245755
Drug: Kudiezi injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kudiezi injection
Study: 30245755
Drug: Routine treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatments
Study: 20145666
Drug: Peptide milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peptide milk (5 mg/day for 12 weeks, then 50 mg/day for 12 weeks)
Study: 18176610
Drug: N-acetyl-L-cysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetyl-L-cysteine (NAC) 100 mg/kg per day as a 6-h i.v. infusion until normalization of bilirubin, ALT and AST values.
Study: 9631802
Drug: N-acetyl-L-cysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetyl-L-cysteine (NAC)
Study: 12526248
Drug: 7 days
Normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 days treatment
Study: 7766742
Drug: 14 days
Normalized name: ponesimod
DrugBank: Ponesimod (DB12016)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 14 days treatment
Study: 12526248
Drug: 21 days
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 21 days treatment
Study: 12526248
Drug: 28 days
Normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 28 days treatment
Study: 12526248
Drug: 14 days
Normalized name: ponesimod
DrugBank: Ponesimod (DB12016)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 14 days treatment (recommended duration)
Study: 10486663
Drug: Physician's decision
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician's decision not to modify treatment
Study: 8595173
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with epidoxorubicin (EPI) 75 mg m‐2 on day 1, leucovorin (LV) 200 mg m‐2 on days 1‐3, and 5-fluorouracil (5‐FU) 450 mg m‐2 on days 1‐3, every 21 days for 7 months
Study: 1910852
Drug: Digoxin treatment
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Digoxin treatment for 8 weeks (group 2)
Study: 1910852
Drug: Discontinued digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Discontinued digoxin treatment 5 weeks post-operation (group 3)
Study: 1910852
Drug: Discontinued digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Discontinued digoxin treatment 3 weeks post-operation (group 4)
Study: 6383135
Drug: Lidocaine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (2 to 3 mg/kg total)
Study: 6383135
Drug: Bretylium Tosylate
Normalized name: Bretylium Tosylate
DrugBank: Bretylium (DB01158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bretylium Tosylate (10 to 30 mg/kg total)
Study: 6383135
Drug: Lidocaine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (2 to 3 mg/kg total) in patients on digitalis preparations
Study: 6383135
Drug: Bretylium Tosylate
Normalized name: Bretylium Tosylate
DrugBank: Bretylium (DB01158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bretylium Tosylate (10 to 30 mg/kg total) in patients on digitalis preparations
Study: 25287853
Drug: Pharmacist-based, patient-centered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-based, patient-centered medication review prior to discharge from hospital
Study: 22797934
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose clopidogrel
Study: 17430214
Drug: Bone marrow
Normalized name: bone marrow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone marrow stem cell therapy
Study: 9492968
Drug: Double paper
Normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double paper source entry (forms entered twice using paper forms)
Study: 2392791
Drug: System 22
Normalized name: methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: System 22 Mizer with 50 mg pentamidine (3 ml fill)
Study: 2392791
Drug: System 22
Normalized name: methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: System 22 Mizer with 50 mg pentamidine (6 ml fill)
Study: 2392791
Drug: Respirgard II
Approvals — FDA: no, EMA: no, PMDA: no
Description: Respirgard II with 50 mg pentamidine (3 ml fill)
Study: 2392791
Drug: Respirgard II
Approvals — FDA: no, EMA: no, PMDA: no
Description: Respirgard II with 50 mg pentamidine (6 ml fill)
Study: 2392791
Drug: System 22
Normalized name: methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: System 22 Mizer with 150 mg pentamidine
Study: 2392791
Drug: Respirgard II
Approvals — FDA: no, EMA: no, PMDA: no
Description: Respirgard II with 150 mg pentamidine
Study: 2392791
Drug: System 22
Normalized name: methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: System 22 Mizer with increased volume of fill (from 3 to 6 ml)
Study: 2392791
Drug: Respirgard II
Approvals — FDA: no, EMA: no, PMDA: no
Description: Respirgard II with increased volume of fill (from 3 to 6 ml)
Study: 27078991
Drug: Floating needle
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Floating needle therapy
Study: 26076014
Drug: IN0 (before
Approvals — FDA: no, EMA: no, PMDA: no
Description: IN0 (before the start of the session at the inlet blood line filled with rinsing solution)
Study: 26076014
Drug: Anti-Xa levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-Xa levels below 0.3 IU/mL at the end of the session
Study: 26076014
Drug: Anti-Xa above
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-Xa above 0.3 IU/mL at the end of the session
Study: 23482444
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (meetings with a physical therapist twice a week for 10-13 weeks)
Study: 19439067
Drug: GLP-1 infusion
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 infusion (1.2 pmol/kg/min)
Study: 21441444
Drug: Blocking endogenous
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blocking endogenous GLP-1 receptor action
Study: 19656148
Drug: PGE(2) gel
Normalized name: PGE-1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PGE(2) gel (2 mg)
Study: 20614859
Drug: Ondansetron (Ond)
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron (Ond) 24 mg QD
Study: 20614859
Drug: Fluoxetine (Fl)
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine (Fl) 5 mg QD + Ondansetron (Ond) 12 mg QD
Study: 20614859
Drug: Fluoxetine (Fl)
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine (Fl) 10 mg QD + Ondansetron (Ond) 24 mg QD
Study: 11347856
Drug: lacidipine (4‐6
Approvals — FDA: no, EMA: no, PMDA: no
Description: lacidipine (4‐6 mg o.d.)
Study: 11347856
Drug: hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: hydrochlorothiazide (HCTZ) (25‐50 mg o.d.)
Study: 1377074
Drug: High-dose aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose aprotinin therapy (2 x 10(6) kallikrein inhibitor units intravenous bolus after induction of anaesthesia followed by continuous infusion of 0.5 x 10(6) kallikrein inhibitor units/h until the end of the operation)
Study: 1377074
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no aprotinin therapy)
Study: 6706301
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg per day of i.v. SAMe
Study: 6706301
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg per day of i.v. SAMe
Study: 6706301
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no SAMe treatment)